Cargando…

Modified oral metronidazole desensitization protocol

The Center for Disease Control guidelines recommend desensitization to metronidazole in patients with trichomoniasis and hypersensitivity to metronidazole. There is only one published oral metronidazole desensitization protocol. The purpose of this study was to design a new, more gradual oral desens...

Descripción completa

Detalles Bibliográficos
Autores principales: Gendelman, Samantha R., Pien, Lily C., Gutta, Ravi C., Abouhassan, Susan R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: OceanSide Publications, Inc. 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124580/
https://www.ncbi.nlm.nih.gov/pubmed/24612959
http://dx.doi.org/10.2500/ar.2014.5.0080
_version_ 1782329643249958912
author Gendelman, Samantha R.
Pien, Lily C.
Gutta, Ravi C.
Abouhassan, Susan R.
author_facet Gendelman, Samantha R.
Pien, Lily C.
Gutta, Ravi C.
Abouhassan, Susan R.
author_sort Gendelman, Samantha R.
collection PubMed
description The Center for Disease Control guidelines recommend desensitization to metronidazole in patients with trichomoniasis and hypersensitivity to metronidazole. There is only one published oral metronidazole desensitization protocol. The purpose of this study was to design a new, more gradual oral desensitization protocol to decrease systemic reactions that may occur when using the previously published protocol. We present two patients with presumed IgE-mediated allergy to metronidazole who underwent oral desensitization using our modified protocol. Case 1 was a 65-year-old woman with trichomoniasis who presented for metronidazole desensitization with a history of intraoperative anaphylaxis and positive skin tests to metronidazole. The patient tolerated six doses of the modified desensitization but developed systemic symptoms of nasal congestion and diffuse pruritus after the 25- and 100-mg doses. Both reactions were treated with intravenous (i.v.) antihistamines. Because of gastrointestinal irritation, the desensitization was completed at a dose of 250 mg orally every 6 hours. Case 2 was a 42-year-old woman with trichomoniasis and a history of hives immediately after administration of i.v. metronidazole who presented for desensitization. The patient had negative skin-prick and intradermal testing to metronidazole. She developed lip tingling and pruritus on her arms 15 minutes after the 10-mg dose. Fexofenadine at 180 mg was given orally and symptoms resolved. She tolerated the rest of the protocol without reaction and received a total dose of 2 g of metronidazole. Our oral metronidazole desensitization for presumed IgE-mediated reactions offers a second option for physicians wishing to use a more gradual escalation in dose.
format Online
Article
Text
id pubmed-4124580
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher OceanSide Publications, Inc.
record_format MEDLINE/PubMed
spelling pubmed-41245802014-08-07 Modified oral metronidazole desensitization protocol Gendelman, Samantha R. Pien, Lily C. Gutta, Ravi C. Abouhassan, Susan R. Allergy Rhinol (Providence) Articles The Center for Disease Control guidelines recommend desensitization to metronidazole in patients with trichomoniasis and hypersensitivity to metronidazole. There is only one published oral metronidazole desensitization protocol. The purpose of this study was to design a new, more gradual oral desensitization protocol to decrease systemic reactions that may occur when using the previously published protocol. We present two patients with presumed IgE-mediated allergy to metronidazole who underwent oral desensitization using our modified protocol. Case 1 was a 65-year-old woman with trichomoniasis who presented for metronidazole desensitization with a history of intraoperative anaphylaxis and positive skin tests to metronidazole. The patient tolerated six doses of the modified desensitization but developed systemic symptoms of nasal congestion and diffuse pruritus after the 25- and 100-mg doses. Both reactions were treated with intravenous (i.v.) antihistamines. Because of gastrointestinal irritation, the desensitization was completed at a dose of 250 mg orally every 6 hours. Case 2 was a 42-year-old woman with trichomoniasis and a history of hives immediately after administration of i.v. metronidazole who presented for desensitization. The patient had negative skin-prick and intradermal testing to metronidazole. She developed lip tingling and pruritus on her arms 15 minutes after the 10-mg dose. Fexofenadine at 180 mg was given orally and symptoms resolved. She tolerated the rest of the protocol without reaction and received a total dose of 2 g of metronidazole. Our oral metronidazole desensitization for presumed IgE-mediated reactions offers a second option for physicians wishing to use a more gradual escalation in dose. OceanSide Publications, Inc. 2014 2014-03-07 /pmc/articles/PMC4124580/ /pubmed/24612959 http://dx.doi.org/10.2500/ar.2014.5.0080 Text en Copyright © 2014, OceanSide Publications, Inc., U.S.A. This publication is provided under the terms of the Creative Commons Public License ("CCPL" or "License"), in attribution 3.0 unported (Attribution Non-Commercial No Derivatives (CC BY-NC-ND)), further described at: http://creativecommons.org/licenses/by-nc-nd/3.0/legalcode. The work is protected by copyright and/or other applicable law. Any use of the work other then as authorized under this license or copyright law is prohibited.
spellingShingle Articles
Gendelman, Samantha R.
Pien, Lily C.
Gutta, Ravi C.
Abouhassan, Susan R.
Modified oral metronidazole desensitization protocol
title Modified oral metronidazole desensitization protocol
title_full Modified oral metronidazole desensitization protocol
title_fullStr Modified oral metronidazole desensitization protocol
title_full_unstemmed Modified oral metronidazole desensitization protocol
title_short Modified oral metronidazole desensitization protocol
title_sort modified oral metronidazole desensitization protocol
topic Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4124580/
https://www.ncbi.nlm.nih.gov/pubmed/24612959
http://dx.doi.org/10.2500/ar.2014.5.0080
work_keys_str_mv AT gendelmansamanthar modifiedoralmetronidazoledesensitizationprotocol
AT pienlilyc modifiedoralmetronidazoledesensitizationprotocol
AT guttaravic modifiedoralmetronidazoledesensitizationprotocol
AT abouhassansusanr modifiedoralmetronidazoledesensitizationprotocol